Cargando…

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

BACKGROUND: Surgical resection of liver metastases arising from colorectal cancer is considered the only curative treatment option. However, many patients subsequently experience disease recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of recurrence followi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gruenberger, Birgit, Scheithauer, Werner, Punzengruber, Robert, Zielinski, Christoph, Tamandl, Dietmar, Gruenberger, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386791/ https://www.ncbi.nlm.nih.gov/pubmed/18439246 http://dx.doi.org/10.1186/1471-2407-8-120

Ejemplares similares

Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases
por: Wimmer, Kerstin, et al.
Publicado: (2016)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
por: Starlinger, P, et al.
Publicado: (2012)

The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy
por: Pereyra, D., et al.
Publicado: (2019)

Side effects during chemotherapy predict tumour response in advanced colorectal cancer
por: Schuell, B, et al.
Publicado: (2005)

Resection of colorectal liver metastases following neoadjuvant chemotherapy
por: Chiappa, A, et al.
Publicado: (2007)

Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
por: Zhu, Dexiang, et al.
Publicado: (2014)

Nodular Regenerative Hyperplasia Secondary to Neoadjuvant Chemotherapy for Colorectal Liver Metastases
por: van den Broek, Maartje A. J., et al.
Publicado: (2009)

Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature
por: Guo, Marissa, et al.
Publicado: (2021)

Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?
por: Pfeiffer, Per, et al.
Publicado: (2018)

The Effect of Induction Chemotherapy with VEGF Inhibition on Tumor Response in Synchronously Metastasized Potentially Resectable Colorectal Cancer
por: Thonhauser, Rebecca, et al.
Publicado: (2023)

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
por: Nordlinger, Bernard, et al.
Publicado: (2008)

Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration
por: Schauer, Dominic, et al.
Publicado: (2014)

Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases
por: Ichida, Hirofumi, et al.
Publicado: (2019)

Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy
por: Serayssol, Chloé, et al.
Publicado: (2019)

Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?
por: Son, Sang-Yong, et al.
Publicado: (2011)

Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases
por: Stremitzer, Stefan, et al.
Publicado: (2020)

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer
por: Desai, Neelam V, et al.
Publicado: (2015)

Preoperative Imaging of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Meta-Analysis
por: van Kessel, Charlotte S., et al.
Publicado: (2012)

Deficiency in Thrombopoietin Induction after Liver Surgery Is Associated with Postoperative Liver Dysfunction
por: Haegele, Stefanie, et al.
Publicado: (2015)

Outcome of Microscopic Incomplete Resection (R1) of Colorectal Liver Metastases in the Era of Neoadjuvant Chemotherapy
por: Ayez, Ninos, et al.
Publicado: (2011)

The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis
por: Liu, Wei, et al.
Publicado: (2016)

Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False
por: Desjardin, Marie, et al.
Publicado: (2019)

Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study
por: Takeda, Kazuhisa, et al.
Publicado: (2022)

DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells
por: Laengle, Johannes, et al.
Publicado: (2018)

Repeat Local Treatment of Recurrent Colorectal Liver Metastases, the Role of Neoadjuvant Chemotherapy: An Amsterdam Colorectal Liver Met Registry (AmCORE) Based Study
por: Dijkstra, Madelon, et al.
Publicado: (2021)

Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease
por: Kieler, Markus, et al.
Publicado: (2016)

Long-term outcomes of patients with 10 or more colorectal liver metastases
por: Allard, M A, et al.
Publicado: (2017)

Is the Clinical Risk Score for Patients with Colorectal Liver Metastases Still Useable in the Era of Effective Neoadjuvant Chemotherapy?
por: Ayez, Ninos, et al.
Publicado: (2011)

Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis
por: Zhang, Yue, et al.
Publicado: (2021)

Impact of perineural invasion on the outcome of patients with synchronous colorectal liver metastases treated with neoadjuvant chemotherapy and surgery
por: Zozaya, Gabriel, et al.
Publicado: (2023)

Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases
por: Liao, Leen, et al.
Publicado: (2023)

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study
por: Piringer, Gudrun, et al.
Publicado: (2023)

Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
por: Dagenborg, Vegar Johansen, et al.
Publicado: (2020)

Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning
por: Kim, Young Il, et al.
Publicado: (2019)

The Immune Phenotype of Isolated Lymphoid Structures in Non-Tumorous Colon Mucosa Encrypts the Information on Pathobiology of Metastatic Colorectal Cancer
por: Mungenast, Felicitas, et al.
Publicado: (2020)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

Increase in lesion enhancement on gadoxetic acid enhanced MRI is associated with complete response to neoadjuvant chemotherapy in colorectal liver metastases
por: Islam, S, et al.
Publicado: (2015)

Upgraded nomograms for the prediction of complications and survival in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by hepatic resection
por: Chen, Qichen, et al.
Publicado: (2021)

Nomogram Incorporating Preoperative Testing Markers for the prediction of Early Recurrence for Colorectal Liver Metastases with Neoadjuvant Chemotherapy followed by Hepatectomy
por: Chen, Qichen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6sei9a3gj20qs7f91rlsm5pr8a